Vasculitis in Geriatric Patients

  • Nages Nagaratnam
  • Kujan Nagaratnam
  • Gary Cheuk
Reference work entry

Abstract

The chapter provides an overview of vasculitis, the prevalence, and mechanisms followed by the clinical management. The incidence of vasculitis is increasing. Of the specific vasculitis, giant cell arteritis of the elderly is the commonest. A useful classification is one based on the size of the vessel, namely, small vessel, small-medium size, and medium to large vessel size affected, although overlap is common. The terms for Wegener’s granulomatosis, Churg-Strauss syndrome, and Henoch-Scholein purpura are changed to granulomatosis with polyangitis (GPA), eosinophilic granulomatosis with polyangitis (EGPA), and IgA vasculitis for Wegener’s granulomatosis, Churg-Strauss, and Henoch-Scholein, respectively. There are several mechanisms involved in the vascular inflammation, namely, immune complex disease, antibody-mediated disease, antibody-dependent cellular cytotoxicity, and endothelial activation, among others. Vasculitis may be primary or secondary. Any part of the body could be affected. The treatment will be very much determined by a careful evaluation, the cause, the extent, and severity of the disease. In the very elderly, vasculitic syndromes have a bad prognosis, majority deteriorating suddenly leading to death or severe functional impairment.

Keywords

Vasculitis Primary secondary vasculitis International Chapel Hill Consensus Conference (CHCC) ANCA associated vasculitides Giant cell arteritis 

References

  1. 1.
    Koldingsnes W, Nossent H. Epidemiology of Wegener’s granulomatosis in Northern Norway. Arthritis Rheum. 2000;43:2481–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Knight A, Ekbom A, Brandt L, Askling J. Increasing incidence of Wegener’s granulomatosis in Sweden. 1975–2001. J Rheumatol. 2006;33:2060–63.PubMedGoogle Scholar
  3. 3.
    Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in northwest Spain: Implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum. 2003;49(3):388–93.CrossRefPubMedGoogle Scholar
  4. 4.
    Weiner M, Goh SM, Mohammad AJ, Hruskova Z, Tanna A, Bruchfeld A, et al. Outcome and treatment of elderly patients with ANCA –Associated Vasculitis. Clin J Am Soc Nephrol.  https://doi.org/10.2215/CJN.00480115.
  5. 5.
    He Q, Shao L. Clinical characteristics of Antineutrophil Cytoplasmic Associated Vasculitis in the Elderly. J Integr Nephol Androl. 2016;3:8–13.CrossRefGoogle Scholar
  6. 6.
    Turcu A, Bielefeld P, Beancenot JF, Lorcerie B, Pfitzenmeyer P. Vasculitis in the elderly. Gerontology. 2002;48(3):174–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Hoganson DD, From AM, Michet CT. Antineutrophil cytoplasmic antibodies vasculitis in the elderly. J Clin Rheumatol. 2008;14(2):78–81.CrossRefPubMedGoogle Scholar
  8. 8.
    Mansi IA, Opran A, Rosner F. ANCA associated small-vessel vasculitis. Am Fam Physician. 2002. http://www.aafp.org/afp/20020415/1615.html
  9. 9.
    Holl-Ulrich K. Vasculitis: New nomenclature of the Chapel Hill consensus conference. Z Rheumatol. 2014;73(9):82333.CrossRefGoogle Scholar
  10. 10.
    Jennette JC, Fak RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis& Rheumatism. 2013;65:1CrossRefGoogle Scholar
  11. 11.
    Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013;17(5):603–6.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kallenberg CGM. Pathogenesis of ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:i59–i63CrossRefPubMedGoogle Scholar
  13. 13.
    Lane SE, Watts R, Scott DGI. Epidemiology of systemic vasculitis. Curr Rheumatol Rep. 2005;7(4):270–275.CrossRefPubMedGoogle Scholar
  14. 14.
    D’Agate V. Anti-neutrophil cytoplasmic antibodies and vasculitis: much more than a disease marker. J Clin Invest. 2002;119 (7):919–921.Google Scholar
  15. 15.
    Gullevin L, Dorner T. Vasculitis: mechanisms involved and clinical manifestations. Arthritis Rev Ther. 2007;9 (suppl2):S9.  https://doi.org/10.1186/ar2193.
  16. 16.
    Suresh E. Diagnostic approach to patients suspected of vasculitis. Postgrad Med J. 2006;82 (970):483–484.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Sinha SN, Luk P.Vasculitic leg ulcers-a review. Primary Intention,2002;1092): www.awma.com.au/journal/1002_04pdf accessed on 22 March 2016.
  18. 18.
    Trepo CG, Thivolet J, Prine AM. Australian antigen and polyarteritis nodosa. Am J Dis Child. 1972;12:3390–3392.Google Scholar
  19. 19.
    Cholty RV. Vasculitis associated HIV infection. J Clin Pathol. 2001;54275- -288278Google Scholar
  20. 20.
    Sansonno D, Dammacco F. Hep C virus, cryoglobulin and vasculitis: immune complex relations. Lancet Infect Dis. 2005;5277–236236Google Scholar
  21. 21.
    Nagaratnam N, Goh TK, Ghougassian D. Campylobacter jejuni induced vasculitis. Postgrad Med J. 1991; 12:636–7.Google Scholar
  22. 22.
    Hom C. Vasculitis and thrombophlebitis. e medicine, March 30 2006. http://www.emedicine.com/ped/topic2390.htm.
  23. 23.
    Mullick FG, McAllister A, Wagner BM, Fenoglio JJ Jr. Drug-related vasculitis. Hum Pathol. 1979;10:313–325.CrossRefPubMedGoogle Scholar
  24. 24.
    Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, et al. The American College of Rheumatology 1990 Criteria for the classification of Wegener’s granulomatosis. Arthritis Rheumat. 1990;33(8):1101–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Vasculitis Foundation. Hypersensitivity Vasculitis. http://www.vasculitisfoundation.org/hypersensitivityvasculitis.
  26. 26.
    uellar ML. Drug-induced vasculitis. Curr Rheumatol Rep. 2002;4:55–9.CrossRefGoogle Scholar
  27. 27.
    Tarzi RM, Pusey CD. Vasculitis: Risks and rewards of treating elderly patients with vasculitis. Nature Rev Nephrol. 2001;7:253–55.  https://doi.org/10.1038/nreph.2011.30.CrossRefGoogle Scholar
  28. 28.
    Tatsis E, Reinhold-Keller E, Steindorf K, Feller AC, Gross WL. Wegener’s granulomatosis associated with renal cell carcinoma. Arthritis Rheum. 1999;42:751–56.CrossRefPubMedGoogle Scholar
  29. 29.
    Greer JM, Longley S, Edwards NL, Elfenbein GJ, Panush RS. Vasculitis associated with malignancy. Experience with 13 patients and literature review. Medicine (Baltimore).1988; 67:220–30.CrossRefGoogle Scholar
  30. 30.
    Longley S, Caldwell JR, Panush RS. Paraneoplastic vasculitis. Unique syndrome of cutaneous angiitis and arthritis with myeloproliferative disorders. Am J Med. 1988.88:1027–30.Google Scholar
  31. 31.
    Pankhurst T, Savage COS, Gordon C, Harper L. Malignancy associated ANCA-associated vasculitis. Rheumatology. 2004;43(12):1532–1535.CrossRefPubMedGoogle Scholar
  32. 32.
    UNC Health Care. ANCA Vasculitis. http://www.unckidney.center.org/kidneyhealthlibrary/unca.html retrieved 6 March, 2015.
  33. 33.
    emedicinehealth.Vasculitis. http://emedicinehealth.com/vasculitisp3_em.htm retrieved 6 March, 2015.
  34. 34.
    Weyand CM, Goromzy JJ. Immune mechanism in medium and large vessel vasculitis. Natyre Reviews Rheumatology. 2013;9:731–740.CrossRefPubMedGoogle Scholar
  35. 35.
    Piggott KS. Mechanisms regulating dysfunctional T cell responses in large vessel vasculitis. https://etdlibrary.emoryview/record/pid/emory:7v6zl. Accessed 18 February 2016.
  36. 36.
    Unwin B, Williams CM, Giliand W. Polymyalgia rheumatic and giant cell arteritis. Am Fam Physician. 2006;74(9): 1547–54.PubMedGoogle Scholar
  37. 37.
    Vos PA, Bijlsma JW, Derksen RH. Polymyalgia rheumatic and temporal arteritis. Ned Tijdschr Geneeskd. 2005;149(35):1932–7.PubMedGoogle Scholar
  38. 38.
    Schmidt J, Warringto KJ. Polymyalgia and giant cell arteritis in older patients: diagnosis and pharmacological management. Drugs Aging. 2011;28(8):651–66.CrossRefPubMedGoogle Scholar
  39. 39.
    Salvarani C, Pipiton N, Versari A, Hunder GG. Clinical features of polymyalgia and giant cell arteritis. Nat Rev Rheumatol. 2012;8(9):509–21.CrossRefPubMedGoogle Scholar
  40. 40.
    Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatic and giant-cell arteritis. Lancet. 2008;372:234–45.CrossRefPubMedGoogle Scholar
  41. 41.
    Kamesh L, Harper L, Savage CO. ANCA-Positive Vasculitis. J Am Soc Nephrol. 2002. 1(7):1953–160.CrossRefGoogle Scholar
  42. 42.
    Roane DW, Grigger DR. An approach to diagnosis and initial management of systemic vasculitis Am Fam Physician 1999. http://www.aafp.org/afp/991001ap/1421.html.
  43. 43.
    Flossman O, Bacon P, de Groot K, Jayne D, Rasmussen N, Seo P, et al. Development of comprehensive disease assessment in systemic vasculitis. Ann Rheum Dis. 2007;67:1004–10.Google Scholar
  44. 44.
    Luqmani RA. State of the art in the treatment of systemic arthritides. Front Immunol. 13 October, 2014. http://dx.doi.org/10,3389/fimmu.2014.00471.
  45. 45.
    Kallenberg, CG. Vasculitis: clinical approach, pathophysiology and treatment. Wien Klin Wochenschr. 2000 ;112(15–16):656–7 .PubMedGoogle Scholar
  46. 46.
    Jennette JC, Falk RJ, Andrassy K, Bacon PA, Chung J, Gross WL, et al. Nomenclature of systemic vasculitides proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.CrossRefPubMedGoogle Scholar
  47. 47.
    Kallenberg CG. Pathogenesis of ANCA associated vasculitis. SAnn Rheum Dis. 2011;70 Suppl 1:159–63.Google Scholar
  48. 48.
    Miller A, Chan M, Wilk A, Misbah SA, Luqmani RA. An approach to the diagnosis of systemic vasculitis revised version with tracked changes removed. Clin Exp Immunol. 2010;160(2):143–160.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Lally L, Spiera R. Current therapies for ANCA-associated vasculitis. Annu Rev Med. 015;66:227–40.Google Scholar
  50. 50.
    Hoffman CS, Kevi GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener’s granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488–98.CrossRefPubMedGoogle Scholar
  51. 51.
    de Groot K, Adu D, Savage COS. The value of pulse cyclophosphamide in ANCA-associated vasculitis. Meta-analysis and critical review. Nephrol DialTransplant. 2001; 2018–2027.Google Scholar
  52. 52.
    Geetha D, Seo P. Advances in therapy for ANCA-associated vasculitis. Curr Rheumatol Rep. 2012;14(6):509–15.CrossRefPubMedGoogle Scholar
  53. 53.
    Hunder CG, Salvarani C, Brown D Jr. Primary cerebral nervous system vasculitis. Is it a single disease? Ann Med. 2008;26(Supp 49): S111.Google Scholar
  54. 54.
    Guillevin L, Pagnoux C. Treatment of ANCA-associated vasculitides. Presse Med. 2007;36(5):922–7.CrossRefPubMedGoogle Scholar
  55. 55.
    Jayne DRW. Update on the European Vasculitis Study Group trials (EUVAS). Curr Opin Rheumatol. 2001;13:48–55.CrossRefPubMedGoogle Scholar
  56. 56.
    Charlton R. Optimal management of giant cell arteritis and polymyalgia rheumatic. Ther Clin Risk Manag. 2012;8:173–9.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Boomsna MM, Stegman CA, Kramer AB, Karsijns M, Piers DA, Tervaert JWC. Prevalence of reduced bone density in patients with anti-neutrophil cytoplasmic antibody associated vasculitis and role of immunosuppressive therapy: a cross sectional study. Osteoporosis Int. 2002;13(1):74–82.CrossRefGoogle Scholar
  58. 58.
    Lane SE, Watt RA, Shepstone L, Scott DG. Primary systemic vasculitis: Clinical features and mortality. Q J Med. 2005;141:78–81.Google Scholar
  59. 59.
    Chen M, Yu F, Zhang Y, Zhao MH. Antineutrophil cytoplasmic autoantibodies associated vasculitis in older patients. Medicine (Baltimore). 2008;87:203–209.CrossRefPubMedGoogle Scholar
  60. 60.
    Cotch MF. The socioeconomic impact of vasculitis. Curr Opin Rheumatol. 2000;112(1):20–3.CrossRefGoogle Scholar
  61. 61.
    Gabriel SE, Sunku J, Salvarani C, O’Fallon WM, Hunder CG. Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997, 40(10):1873–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Nester G, Sonnenblick M, Fried Lander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15 year survey of 43 patients. J Rheumatol. 1994;21(7): 1283–6.Google Scholar
  63. 63.
    Louwen R, Hayes P. Is there an unrecognised role for Campylobacter infections in (chronic) inflammatory diseases? World J Clin Infect Dis. 2013;3(4):58–69.Google Scholar
  64. 64.
    Nagaratnam N, Goh TK, Ghoughassian D. Campylobacter jejuni-induced vasculitis. BJCP. 1990;44(11):636–637Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Nages Nagaratnam
    • 1
  • Kujan Nagaratnam
    • 1
  • Gary Cheuk
    • 2
  1. 1.The University of SydneyWestmead Clinical SchoolWestmeadAustralia
  2. 2.Rehabilitation and Aged Care ServiceBlacktown-Mt Druitt HospitalMount DruittAustralia

Personalised recommendations